Yükleniyor... / Loading...
This study collects blood, urine and stool samples to monitor patients with metastatic or unresectable colorectal cancer during treatment. Eligible patients are those about to undergo first-, second- or third-line therapy with histologically confirmed disease and known KRAS status. It was conducted as a study without a formal phase and has been completed.
The summary above is a plain-language rendering of the official record. The original English title is shown for reference.
Criteria are reproduced from the ClinicalTrials.gov record in the original English. Only the trial team can determine eligibility.
Inclusion Criteria: * All patients with metastatic/unresectable colorectal cancer who will undergo first, second, or third line therapy; the participating investigator will select treatment, however, patients with Kras wild type must receive anti-EGFR therapy to be eligible for this study * Subject consent to enrollment on the protocol * Histologically confirmed metastatic or un-resectable colorectal cancer, known Kras status; knowledge of other mutations is optional * Willingness to undergo biopsy at the time of progression * Willingness to follow the study instructions for collection of specimens * Available archival tissue